<DOC>
	<DOCNO>NCT02278419</DOCNO>
	<brief_summary>The purpose study evaluate efficacy simeprevir combination sofosbuvir 8 12 week versus historical control , respect percentage participant sustain virologic response 12 week end treatment ( SVR12 ) overall population .</brief_summary>
	<brief_title>An Efficacy Safety Study 8 12-Week Treatment Regimen Simeprevir Combination With Sofosbuvir Treatment-Naive Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection</brief_title>
	<detailed_description>This partly randomize , open-label ( identity study drug know volunteer study staff ) , multicenter ( one hospital medical school team work medical research study ) study . The study consist screen period 4 week , open-label treatment period 8 week 12 week , post-treatment follow-up period 24 week end treatment ( EOT ) . Participants without cirrhosis assign Group A wherein half participant receive 8 week treatment Group A1 remain participant receive 12 week treatment Group A2 . Participants cirrhosis , assign Group B receive simeprevir combination sofosbuvir 12 week . The duration participation participant , include screen period , approximately 36 40 week 8 12 week treatment , respectively . Efficacy primarily assess percentage participant SVR12 . Participants ' safety evaluate throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Participant must hepatitis C virus ( HCV ) genotype 4 infection ( confirmed screening ) Participant must HCV ribonucleic acid ( RNA ) great ( &gt; ) 10,000 international unit per milliliter ( IU/mL ) screen In participant cirrhosis , document hepatic imaging procedure ( ultrasound , compute tomography [ CT ] scan , magnetic resonance image [ MRI ] ) within 6 month baseline ( Day 1 ) exclude hepatocellular carcinoma require A woman childbearing potential must negative serum ( beta human chorionic gonadotropin screen negative urine pregnancy test Day 1 first dose study drug Females childbearing potential male female partner childbearing potential must agree use 2 highly effective contraceptive method ( one barrier method ; eg , condom diaphragm ) Day 1 ( baseline ) continue 30 day end treatment ( EOT ) ( longer dictate local regulation ) , heterosexually active , vasectomized male subject female subject vasectomized partner , female ( subject partner male subject ) nonchildbearing potential ( ie , postmenopausal least 2 year surgically sterile ) Participant evidence clinical hepatic decompensation ( history current evidence ascites , bleed varix , hepatic encephalopathy ) Participant liver disease nonHCV etiology . This include , limited , acute hepatitis A , drug alcoholrelated liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency , nonalcoholic steatohepatitis , primary biliary cirrhosis , nonHCV liver disease consider clinically significant investigator Participant infected/coinfected nongenotype 4 HCV Participant active clinically significant disease clinically significant finding screen medical history , physical examination , laboratory test electrocardiogram ( ECG ) recording , investigator 's opinion , would compromise participant 's safety could interfere participant participate complete study Participant history malignancy within 5 year screen visit ( exception : skin carcinoma , carcinoma situ cervix , malignancy opinion investigator consider cure minimal risk recurrence )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Healthy</keyword>
</DOC>